[go: up one dir, main page]

PE20110382A1 - Tratamiento de enfermedad autoinmunitaria e inflamatoria - Google Patents

Tratamiento de enfermedad autoinmunitaria e inflamatoria

Info

Publication number
PE20110382A1
PE20110382A1 PE2011000140A PE2011000140A PE20110382A1 PE 20110382 A1 PE20110382 A1 PE 20110382A1 PE 2011000140 A PE2011000140 A PE 2011000140A PE 2011000140 A PE2011000140 A PE 2011000140A PE 20110382 A1 PE20110382 A1 PE 20110382A1
Authority
PE
Peru
Prior art keywords
seq
treatment
autoimmune
inflammatory disease
cdrs
Prior art date
Application number
PE2011000140A
Other languages
English (en)
Inventor
Stuart Leung
Lixin Li
Xeubin Liu
Hongao Lu
Ping Tsui
Jingwu Zang
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20110382A1 publication Critical patent/PE20110382A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN ANTICUERPO HUMANO, HUMANIZADO O QUIMERICO QUE SE UNE AL CD127 HUMANO, EL CUAL COMPRENDE: A) UNA CADENA PESADA CON LOS CDRs DE SEQ ID NO: 73, 74, 75; B) UNA CADENA LIGERA CON LOS CDRs DE SEQ ID NO: 76, 77, 78; C) UNA REGION VARIABLE DE CADENA PESADA DE SEQ ID NO: 71; Y D) UNA REGION VARIABLE DE CADENA LIGERA DE SEQ ID NO: 72. DICHO ANTICUERPO INHIBE LA UNION DE IL-17 CON IL-7R INHIBIENDO ASIMISMO LA PRODUCCION DE LA IL-17, IFN-y INDUCIDA POR LA IL-17 MEDIANTE LAS CELULAS TH17 SIENDO UTIL EN EL TRATAMIENTO DE LA ESCLEROSIS MULTIPLE
PE2011000140A 2008-08-08 2009-08-07 Tratamiento de enfermedad autoinmunitaria e inflamatoria PE20110382A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8729408P 2008-08-08 2008-08-08
US16980109P 2009-04-16 2009-04-16
US21862709P 2009-06-19 2009-06-19

Publications (1)

Publication Number Publication Date
PE20110382A1 true PE20110382A1 (es) 2011-06-27

Family

ID=41382165

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000140A PE20110382A1 (es) 2008-08-08 2009-08-07 Tratamiento de enfermedad autoinmunitaria e inflamatoria

Country Status (23)

Country Link
US (2) US20110287000A1 (es)
EP (1) EP2318442A1 (es)
JP (1) JP2011530533A (es)
KR (1) KR20110044777A (es)
CN (1) CN102177179A (es)
AR (1) AR072985A1 (es)
AU (1) AU2009279471A1 (es)
BR (1) BRPI0916945A2 (es)
CA (1) CA2733432A1 (es)
CL (1) CL2011000269A1 (es)
CO (1) CO6341640A2 (es)
CR (1) CR20110118A (es)
DO (1) DOP2011000041A (es)
EA (1) EA201100150A1 (es)
IL (1) IL211034A0 (es)
MA (1) MA32621B1 (es)
MX (1) MX2011001477A (es)
NZ (1) NZ590994A (es)
PE (1) PE20110382A1 (es)
TW (1) TW201018482A (es)
UY (1) UY32038A (es)
WO (1) WO2010017468A1 (es)
ZA (1) ZA201100974B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8171134B2 (en) * 2009-03-18 2012-05-01 At&T Intellectual Property I, L.P. Methods and apparatus to characterize and predict network health status
MA34004B1 (fr) 2010-01-28 2013-02-01 Glaxo Group Ltd Protéines de liaison à cd127
US20130046015A1 (en) * 2010-02-11 2013-02-21 Robert C. Axtell Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease
AU2014201648B2 (en) * 2010-02-24 2016-05-12 Rinat Neuroscience Corp. Antagonist anti-il-7 receptor antibodies and methods
AR080291A1 (es) * 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
JPWO2011152503A1 (ja) * 2010-06-02 2013-08-01 大日本住友製薬株式会社 自己免疫疾患またはアレルギー疾患の治療剤
US20130295111A1 (en) * 2010-08-10 2013-11-07 The Scripps Research Institute Methods and compositions for treating disorders associated with hyperactive immune system
HUE053720T2 (hu) 2011-01-14 2021-07-28 Univ California ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
EP2583980A1 (en) 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
FR2988479B1 (fr) * 2012-03-23 2014-12-19 Hospices Civils Lyon Procede de determination de la susceptibilite aux infections nosocomiales
CN113144178B (zh) * 2014-04-29 2024-10-18 康达医药科技有限公司 采用精氨酸酶i调节免疫系统的方法和组合物
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
WO2016044189A1 (en) * 2014-09-15 2016-03-24 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
MX2017004975A (es) 2014-10-18 2017-06-30 Pfizer Composiciones de anticuerpos anti-il-7r.
AR103891A1 (es) * 2015-03-11 2017-06-14 Glaxosmithkline Ip Dev Ltd Proteínas de unión a tslp, ácido nucleico aislado que la codifica, vector y célula hospedadora que lo comprenden, método para producir dicha proteína, su uso para fabricar un medicamento, composición farmacéutica y kit que la comprenden
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CA2997809A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
RS59223B1 (sr) 2016-02-29 2019-10-31 Ose Immunotherapeutics Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera
MX2019006577A (es) * 2016-12-09 2019-10-07 Ose Immunotherapeutics Anticuerpos y polipeptidos dirigidos contra cd127.
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
KR20230128134A (ko) * 2019-01-22 2023-09-01 브리스톨-마이어스 스큅 컴퍼니 Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
CN117343173A (zh) * 2019-03-07 2024-01-05 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
MX2022005083A (es) 2019-10-28 2022-07-19 Medimmune Ltd Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos.
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
EP4103605A1 (en) 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
AU2021219839A1 (en) 2020-02-13 2022-08-25 Amgen Inc. Formulations of human anti-TSLP antibodies and methods of treating inflammatory disease
MX2022010120A (es) 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
JP2023551935A (ja) 2020-12-02 2023-12-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｉｌ－７結合タンパク質および医学的療法におけるそれらの使用
AR129445A1 (es) 2022-05-27 2024-08-28 Glaxosmithkline Ip Dev Ltd USO DE PROTEÍNAS DE UNIÓN A TNF-a Y PROTEÍNAS DE UNIÓN A IL-7 EN EL TRATAMIENTO MÉDICO
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
EP4455308A1 (en) 2023-04-24 2024-10-30 Les Laboratoires Servier Il-7r gene signatures
AU2024284143A1 (en) * 2023-06-07 2025-10-23 Fbd Biologics Limited Engineered il-7 variants and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194375A (en) * 1989-06-15 1993-03-16 Immunex Corporation Dna encoding interleukin-7 receptors and methods of use
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994028160A1 (en) * 1993-06-01 1994-12-08 Toray Industries, Inc. Monoclonal antibody, process for producing the same, and use thereof
US20050054054A1 (en) * 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
WO2005123774A2 (en) * 2004-06-15 2005-12-29 Erol Fikrig Antibodies to west nile virus polypeptides
WO2006052660A2 (en) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Il-7 receptor blockade to suppress immunity
GT200600065A (es) * 2005-02-14 2006-10-02 Anticuerpos para interleucina-17f y otros antagonistas de la señalizacion de il-17f y sus usos
CA2513350A1 (en) * 2005-03-02 2006-09-02 Sydney West Area Health Service Treatment for multiple sclerosis
GB2434578A (en) * 2006-01-26 2007-08-01 Univ Basel Transgenic animals

Also Published As

Publication number Publication date
MA32621B1 (fr) 2011-09-01
AR072985A1 (es) 2010-10-06
US20100040616A1 (en) 2010-02-18
UY32038A (es) 2010-03-26
CN102177179A (zh) 2011-09-07
MX2011001477A (es) 2011-03-25
DOP2011000041A (es) 2011-02-28
EA201100150A1 (ru) 2011-10-31
WO2010017468A1 (en) 2010-02-11
BRPI0916945A2 (pt) 2015-11-24
CA2733432A1 (en) 2010-02-11
KR20110044777A (ko) 2011-04-29
NZ590994A (en) 2012-09-28
CL2011000269A1 (es) 2012-07-20
CR20110118A (es) 2011-07-28
AU2009279471A1 (en) 2010-02-11
CO6341640A2 (es) 2011-11-21
ZA201100974B (en) 2012-10-31
IL211034A0 (en) 2011-04-28
EP2318442A1 (en) 2011-05-11
US20110287000A1 (en) 2011-11-24
JP2011530533A (ja) 2011-12-22
TW201018482A (en) 2010-05-16

Similar Documents

Publication Publication Date Title
PE20110382A1 (es) Tratamiento de enfermedad autoinmunitaria e inflamatoria
CY1125252T1 (el) Σιωπηλες παραλλαγες fc των anti-cd40 αντισωματων
PE20121361A1 (es) Antagonistas de pcsk9
EA201070596A1 (ru) Гуманизированные антитела против tl1a
PE20121034A1 (es) Anticuerpos anti-factor d humanizados
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
PE20120429A1 (es) Proteinas de enlace de miostatina
EA200800812A1 (ru) Композиции антитела против cd3
MY166776A (en) Humanised anti-ctla4 antibodies
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
MX2019006188A (es) Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo.
GT200900167A (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano.
PE20142245A1 (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
MX369220B (es) Moleculas que enlazan cd3 capaces de enlazar a cd3 humano y no humano.
PE20080846A1 (es) Composiciones y metodos relacionados con los anticuerpos receptores de glucagon
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
PE20140814A1 (es) Anticuerpos contra la angiopoyetina 2 humana
EA201070270A1 (ru) Пептиды с пониженным уровнем образования димеров
MA31925B1 (fr) Anticorps bivalents bispécifiques
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
EP4371570A3 (en) Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
PE20110801A1 (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f

Legal Events

Date Code Title Description
FX Voluntary withdrawal